Table 1.

Patient characteristics

Parameter n (%)/median [range]Overall (n = 113)Decitabine (N = 73)Azacitidine (N = 40)
Age, years70 [44-88]70 [44-88]70 [53-84]
WHO diagnosis
 RCUD15 (13)10 (14)5 (13)
 RCMD40 (35)29 (40)11 (28)
 MDS with ringed sideroblasts3 (3)2 (3)1 (3)
 MDS-EB25 (22)14 (19)11 (28)
 5q-2 (2)02 (5)
 MDS-U6 (5)6 (8)0
 MDS/MPN-U6 (5)2 (3)4 (10)
 CMML16 (14)10 (14)6 (15)
Therapy-related MDS20 (18)13 (18)7 (18)
≥2 cytopenias68 (50)34 (47)22 (55)
Transfusion dependence59 (52)39 (53)20 (50)
BM blasts percentage3 [0-10]2 [0-10]3 [0-10]
Blasts ≥5%32 (28)21 (29)11 (27)
Cytogenetic risk (IPSS)
 Good69 (61)43 (63)26 (65)
 Intermediate30 (27)17 (23)13 (33)
 Poor11 (10)10 (14)1 (3)
IPSS risk group
 Low22 (19)16 (22)6 (15)
 Intermediate-191 (81)57 (78)34 (85)
IPSS-R risk group
 Very low14 (12)10 (14)4 (10)
 Low41 (36)25 (34)16 (40)
 Intermediate34 (30)21 (29)13 (33)
 High23 (20)16 (22)7 (18)
 Very high1 (1)1 (1)0
MDACC LR-MDS score
 Low13 (11)10 (14)3 (8)
 Intermediate52 (46)35 (48)14 (43)
 High48 (42)28 (38)20 (40)
Prior therapy
 Growth factors22 (19)12 (16)10 (25)
 Others9 (8)5 (7)4 (10)
Time from diagnosis, weeks5 [1-271]6 [1-216]4 [1-271]
  • BM, bone marrow; MDACC, MD Anderson Cancer Center; MDS-EB, MDS with excess blasts; MDS-U, MDS, unclassified; MPN-U, myeloproliferative neoplasm, unclassified; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; WHO, World Health Organization.